DMT Shows Longer Antidepressant Effects Than Ketamine

For people battling severe depression who don't respond to traditional medications, a naturally occurring psychedelic compound might offer relief that lasts longer than existing fast-acting treatments.

Researchers at the Federal University of Rio Grande do Norte in Brazil compared DMT, a fast-acting hallucinogen found in various plants and animals, with S-ketamine, the only approved rapid-acting antidepressant currently available. The results, published in Neuropharmacology, showed that DMT's benefits lasted significantly longer in laboratory tests.

The study tested both compounds on mice experiencing learned helplessness, a condition that mimics human depression symptoms like lack of motivation and behavioral despair. Both treatments worked quickly to reverse depressive behaviors within 24 hours, but their staying power differed dramatically.

S-ketamine's effects wore off after just 28 hours. DMT, however, kept working for a full eight days after a single dose.

The research also revealed that DMT helped restore the mice's interest in pleasurable activities, a crucial measure since many depression patients lose the ability to enjoy things they once loved. Five days after treatment, mice given either drug showed normal interest in sweet water, demonstrating that both compounds effectively treated this symptom called anhedonia.

Social connection played an important role in recovery. Mice housed in groups responded better to both treatments than isolated mice, though all animals still experienced significant benefits from the medications.

The Bright Side

This research addresses a critical gap in depression treatment. Current antidepressants take weeks to work, leaving patients vulnerable during a dangerous waiting period. About one-third of people with major depression don't respond to traditional medications at all.

"Current antidepressants often take weeks to produce clinical improvement, which represents a major limitation, especially for patients with severe symptoms," said lead researcher Professor Elaine Gavioli. While S-ketamine offers faster relief, its clinical use faces limits due to side effects and potential for misuse.

DMT's longer-lasting effects could mean fewer treatments and better sustained relief for patients. Early clinical trials with humans have already shown that inhaling or injecting DMT safely alleviates depressive symptoms, making this animal research particularly relevant for future human applications.

The findings offer genuine hope that psychedelic compounds might become powerful tools for treating severe, treatment-resistant mental health conditions where other options have failed.